Plasma Hydrogen Sulfide, Nitric Oxide and Stress Hyperglycemia in Acute Myocardial Infarction

• Conditions: Myocardial Infarction
• Interventions: Other: Measurement of hydrogen sulfide

• Registration Number: NCT03829605
• Lead Sponsor: Assiut University

Brief Summary

Acute myocardial infarction (AMI) can cause heart failure, an irregular heartbeat, cardiogenic shock, or cardiac arrest. It is the major cause of morbidity and mortality in the general population. The diagnosis of AMI is complex basing on the clinical history, physical examination, cardiac markers, and a chest radiograph. Besides, considering that the mechanisms linking activation of inflammation and ACS are complex as well, progress in diagnosis and therapy improves little

Detailed Description

The World Health Organization (WHO) indexed cardiovascular disease (CVD) as a leading foundation for human death in developing as well as developed countries. Ischemic necrosis of the myocardium is called myocar¬dial infarction. Despite improvements in medical and interventional therapies in recent years, acute myocar¬dial infarction is still an important cause of mortal¬ity and morbidity. Hydrogen sulfide (H2S) is a colorless, water-soluble gas and is an endogenously produced labile diffusible mediator with multiple roles in the cardiovascular system in health and disease. H2S is endogenously generated, and cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) are key enzymes involved in its biological production. Once interacting with carbon monoxide and nitric oxide, H2S will initiate a unique gaseous signaling net¬work and participate in the regulation of multiple patho¬physiological processes. Plasma H2S levels negatively correlated with HbA1c, duration of diabetes, and systolic and diastolic blood pressures.

Study Timeline

• Status Verified: 2019-02
• Study First Submitted: 2019-02-01
• Study First Submitted QC: 2019-02-01
• Last Update Submitted: 2019-02-01
• Study First Posted: 2019-02-04
• Last Update Posted: 2019-02-04
• Study Start: 2019-02-15
• Primary Completion: 2019-04-20
• Study Completion: 2019-05-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Patients with confirmed diagnosis of AMI-
• Patients of age 18 years or more who are willing to participate in the study and give their consent for same.

Exclusion Criteria

• Patients with congenital heart diseases, alcoholics with a past history of liver disease, pulmonary embolus, sepsis, chest trauma, and renal failure were excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group I:	Measurement of hydrogen sulfide	Fifty AMI patients on admission
Group II:	Measurement of hydrogen sulfide	The previous AMI patients after 12 hours

Primary Outcome Measures

Name	Time	Method
The mean difference of hydrogen sulfide before and after treatment	12 hours	Hydrogen sulfide mean difference will be measured by ELISA in myocardial infarction.